BECN1 and nonpapillary renal cell carcinoma: Indeed, our in ovo data confirmed this hypothesis in BAP1-deficient ccRCC cells treated with the Tat-BECN1 peptide, as tumor growth was significantly compromised compared to the Tat-scrambled peptide control.